A detailed history of Jpmorgan Chase & CO transactions in Medicinova Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 11,276 shares of MNOV stock, worth $22,664. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,276
Previous 5,376 109.75%
Holding current value
$22,664
Previous $7,000 228.57%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$1.13 - $2.1 $6,666 - $12,390
5,900 Added 109.75%
11,276 $23,000
Q2 2024

Aug 12, 2024

SELL
$1.28 - $1.57 $35,968 - $44,117
-28,100 Reduced 83.94%
5,376 $7,000
Q1 2024

May 10, 2024

SELL
$1.28 - $1.65 $127,944 - $164,929
-99,957 Reduced 74.91%
33,476 $48,000
Q4 2023

Feb 12, 2024

SELL
$1.38 - $2.06 $2,681 - $4,002
-1,943 Reduced 1.44%
133,433 $200,000
Q3 2023

Nov 14, 2023

SELL
$2.01 - $2.6 $66,000 - $85,373
-32,836 Reduced 19.52%
135,376 $282,000
Q2 2023

Aug 11, 2023

SELL
$2.09 - $2.43 $17,062 - $19,838
-8,164 Reduced 4.63%
168,212 $386,000
Q1 2023

May 11, 2023

SELL
$1.95 - $2.54 $142,289 - $185,341
-72,969 Reduced 29.26%
176,376 $380,000
Q4 2022

Feb 13, 2023

SELL
$1.97 - $2.66 $96,000 - $129,624
-48,731 Reduced 16.35%
249,345 $511,000
Q3 2022

Nov 14, 2022

BUY
$2.1 - $2.6 $5,670 - $7,020
2,700 Added 0.91%
298,076 $647,000
Q2 2022

Aug 11, 2022

SELL
$2.31 - $3.14 $29,799 - $40,506
-12,900 Reduced 4.18%
295,376 $747,000
Q1 2022

May 11, 2022

BUY
$2.19 - $2.81 $15,570 - $19,979
7,110 Added 2.36%
308,276 $823,000
Q4 2021

Feb 10, 2022

BUY
$2.61 - $4.42 $62,694 - $106,172
24,021 Added 8.67%
301,166 $807,000
Q3 2021

Nov 12, 2021

BUY
$3.4 - $4.24 $942,293 - $1.18 Million
277,145 New
277,145 $1.05 Million

Others Institutions Holding MNOV

About MEDICINOVA INC


  • Ticker MNOV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,046,200
  • Market Cap $98.6M
  • Description
  • MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...
More about MNOV
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.